INTRODUCTION
Bone is unique in its self-healing capacity as it heals without fibrous scar tissue formation. The process resembles the embryonic bone formation in utero, either via the intramembranous or the endochondral route; in fracture healing cells migrate in and differentiate from mesenchymal stem cells into mature osteoblasts or chondroblasts, forming a callus. By remodelling and later modelling bones unite without a scar and in some cases even without radiographic traces.
When healing does not occur, the consequences of a fracture may be detrimental to the individual: leaving a true pseudarthrosis, or a malunited bone resulting in poor function and destruction of joints, or infection of the fracture which may lead to permanently draining sinuses or even amputation. Nature's capacity to heal bones is enormous and therefore our job as surgeons to promote healing is in most cases quite simple. Fractures should be reduced to as close an anatomical position as possible, and immobilised for a certain period of time until enough callus to carry load has been formed. During the 20th century methods for fracture fixation became more sophisticated, and for certain fractures this has changed the outcome dramatically. Our understanding of fracture healing has also improved; the molecular mechanisms and the sequences of healing are partially known. However, we still poorly understand why fractures do not unite in every case, even if a large fracture gap, a poorly reduced fracture or improper immobilisation regularly lead to delayed union or nonunion (1).
Since a significant part of fractures does not heal properly, there is still a need for augmentation of the bone healing process. In 1965 Marshall Urist coined the term bone morphogenetic protein when he detected that a protein extract from bone lead to new bone formation in muscle (2). In the 1980's the amino acid structures of the bone morphogenetic proteins were detected, and the proteins were sequenced and cloned. In the 1990's, after pre-clinical testing in animals from mouse to non-human primates, recombinant proteins started to be tested in human models. Recombinant human bone morphogenetic protein 2 (rhBMP-2) and recombinant human bone morphogenetic protein 7 (rhBMP-7) or osteogenic protein 1 (OP-1) has so far been used clinically. At present, there are several published clinical studies on the effects of BMPs in bone healing or in delayed unions/ non-unions and several studies have reported the effects in fusion of the lumbar spine (3-5). In this review the clinical studies published on long bone healing will be summarized; one study on fibular osteotomies, one study each on the BMPs used in tibial pseudarthrosis or in allograft pseudarthrosis and two studies on acute tibial fractures (6-10).
In the present review BMP denotes the recombinant human proteins and not the term that Urist coined; rhBMPs are not necessarily identical to the proteins produced in the human body as there are posttranslational modifications of the proteins in vivo that do not take place when produced in vitro (phosphorylations and glucosylations of the protein). The amino acid sequence of the rhBMPs is though identical to the ones produced in vivo.
REVIEW OF STUDIES
Four randomised prospective controlled studies have used either OP-1 or rhBMP-2 to promote bone healing.
Geesink et al (1999) made a human critical size defect during high tibial osteotomies, as they resected a part of the fibula (10) . In twenty-four patients who underwent a high tibial osteotomy for osteoarthritis of the knee approximately 15 mm of the fibula was resected. The fibular defect was treated either with demineralised bone (DMB), with OP-1 in collagen type 1 as a carrier, with only collagen type 1, or the defect was left untreated. 2.5 mg of OP-1 was mixed with one gram of purified bovine type 1 collagen reconstituted with 3 ml of 0.9% NaCl. Patients were evaluated by the Hospital for special surgery score, by plain radiographs and by bone mineral density measurement using DXA. Mean defect size as measured on DXA was 15.4 mm to 16.4 mm in the four groups. Clinical results for the high tibial osteotomy operation were similar between the groups. Two patients had complications in wound healing of the fibula, one in the OP-1 group and one in the collagen only group. Patients treated only with collagen or leaving the defect untreated showed little bone reaction. All patients treated with DMB and 5 of the 6 treated with OP-1 showed new bone formation from 6 weeks and onwards. After 6 weeks bridging was found in 4 patients treated with OP-1 and one patient with DMB. After 10 weeks this had increased to 5 in the OP-1 group and four in the DMB group. Patients in the collagen only or untreated groups showed no bridging at 10 weeks. At twelve months there was bone formation with bridging of the fibular defect in 4 of 6 patients in the DMB group, 5 of 6 in the OP-1 group and none in both the untreated and type 1 collagen carrier group. Interestingly, when patients graded their pain at the fibular osteotomy side, 3 out of 6 patients treated with OP-1 had some pain, while all patients in the three other groups were pain free.
Bone mineral density in the defect side was highest in the DMB group with 1.01 g/cm 3 followed by OP-1 (0.82 g/cm 3 ) at 12 months. BMD in those treated with only collagen or left untreated was only 0.44 g/cm 3 .
In a supplement to the Journal of Bone and Joint Surgery [Am] in 2001, the effect of OP-1 in the treatment of tibial nonunions were reported by Friedlaender et al (9). In this study 122 patients with tibial non-unions were treated by intramedullary nailing and randomised to augmentation by either OP-1 or fresh autograft. Nonunions were defined as by FDA: A fracture that is not united after 9 months and where there has been no evidence of increased healing during the last 3 months. In more than 90% of the patients a new intramedullary nail was inserted, while in the rest of the patients a nail that was already in place was kept. Sixty-three tibial non-unions were treated with OP-1 and 61 were treated with bone autograft. Surgeons were aware of which treatment group the patient belonged to. Three point five mg of OP-1 were mixed with 1 g of type 1 bovine collagen and reconstituted in saline. A maximum dose of 2 units of OP-1 were used depending on the size of the defect after debridement. The two treatment groups were similar in most aspects preoperatively, apart from a higher prevalence of atrophic non-unions in the OP-1 group. Forty-seven of the 63 non-unions were treated with 1 OP-1 unit. The amount of autograft used was not reported. Ninetytwo % of the intramedullary rods were locked. The patients in the autograft group had a significantly higher blood loss and also reported donor site pain postoperatively, which still persisted in 13% after 12 months. Osteomyelitis was reported at the fracture site in 21% of patients treated with bone autograft compared to only 3% in those receiving OP-1. The consequences for the patients of this difference in infection rate was not reported, as was also the case with whether a higher number of wound healing problems occurred in the autograft group compared to the OP-1 group.
Success was in this study defined as full weight bearing with less than severe pain at the fracture site. With these criteria 81% of the OP-1 group and 85% of the autograft group were successful. By 9 months follow up 5% of the OP-1 treated patients and 10% of those receiving autograft had been reoperated for one reason or another.
Radiographic evidence of bone bridging was evident in 75% in the OP-1 group compared to 84% in the autograft group (non significant difference at 9 months). When applying bridging of 3 or 4 cortices as criteria for radiographic healing, 62% in the OP-1 group and 74% in the autograft treated group were healed.
Maniscalco et al reported a clinical study using OP-1 in fresh closed tibial fractures (8). A monolateral external fixator was mounted in all patients mean six days after injury. Fourteen patients were randomized to either OP-1 or control. OP-1 was injected through a 1 cm incision via a 5 mm drill hole in the fracture line. Healing was assessed by plain radiography and ultrasound. In the OP-1 group healing was confirmed from day 120 to 165, average day 135. In the control group healing was recorded from day 121 to 162, average day 131. In the OP-1 group the fixator was removed day 169 (range 130-170. In the control group the fixator was removed day 151 (range 97-175). Six of the 7 fractures in the OP-1 group consolidated without reintervention, no details were given of the seventh patient. All 7 fractures in the control group consolidated, but one refractured after 1 month.
In 2002 Govender et al (7) reported the effect of rhBMP-2 in open tibial shaft fractures treated with intramedullary nails. Patients were randomised to either rhBMP-2 on an absorbable collagen sponge of type 1 bovine collagen or to standard of care treatment without any additional intervention. The high dose group received 1.5 mg/ml rhBMP-2, the low dose group received 0.75 mg/ml, in the control group no sponge or any additional treatment was used. The high dose group received a maximum of 12 mg rhBMP-2 and the low dose group 6 mg rh-BMP-2. More than 90% of the patients in both the high dose and low dose group received the whole collagen sponge. The BMP-2 was implanted at the time of definitive wound closure, up till 14 days after initial fracture treatment. Patients were treated with either reamed or unreamed intramedullary nails and locking of the nails was left to the discretion of the treating surgeon. More than 94% of the patients were followed for a complete 12 months' period.
The end-point in this study was any re-operation to promote fracture healing, including selfdynamisation of the nail by breakage of locking screws. The number of reoperations in the control group was 46%, and was reduced to 26% in the high dose BMP-2 group. It was an intermediate effect in the low dose group with 37% reoperations. Combined radiographic and clinical end points with healing of 3 or 4 cortices and no pain while fully weight bearing, showed an increased healing of the fractures after 10 weeks in the high dose BMP-2 group. This difference persisted throughout the study. The low dose BMP-2 group were again intermediate between the control group and the high dose group. High dose BMP-2 also seemed to stimulate healing of the skin: After 6 weeks 83 % of the wounds were healed in the high dose group compared to 65% in the control group. A reduction in infection rate was found in the Gustilo III A/III B open fractures where 44 % had superficial or deep infection in the control group compared to 24% in the high dose BMP-2 group. The high dose BMP-2 group experienced less pain early on, probably as an effect of earlier stabilisation of the fracture and also perhaps due to earlier wound healing.
An unbiased endpoint in this study was hardware failure of the nail or of the locking screws. It was reduced from 22% in the control group to 11% in the high dose group.
A confounding factor was the distribution of reamed and unreamed nails. In the control group more unreamed nails were used compared to the high dose BMP-2 group. When analysing the reamed nails in the control group and comparing them to the unreamed nails treated with high dose BMP-2 the results seemed to be similar. However, also with the use of reamed nails there seemed to be acceleration in healing of the fractures up to 24 weeks. With the power of this study it could not be shown that BMP-2 had any additional effect of the primary end point secondary intervention to promote healing in the reamed group analysed per se.
In the latest study published Delloye et al reported on the treatment of allograft fractures or non unions. Structural allografts with non unions or fractures after resection of malignant bone tumours were followed 1-5 years after application of recombinant human BMPs. Three of the non unions occurred within the allograft itself and 3 occurred at the allograft host junction. Three patients were treated with 12 mg of rhBMP-2 and the 3 others with 7mg of rhBMP-7 (OP-1). In this study they found neither healing of allograft fractures nor union of allograft host junction. An interesting finding in this study was the lack of tumour recurrence with the use of BMP after a mean follow up of 39 months (6).
DISCUSSION
Since Marshall Urist first coined the term bone morphogenetic protein, many peptides responsible for this effect in the extracts of bone have been found, sequenced and cloned (11) . The BMP family of proteins has a unique ability to induce either bone or cartilage formation, in fact they are the only known growth factors to do this. It could be argued that the term growth factor is perhaps misleading in that they are in addition differentiation and migration factors determining mesenchymal stem cells to develop into either osteoblasts or chondroblasts (12) , and they attract progenitor cells by chemotaxis (13) . The differentiation and migration effects are probably more important for bone healing than the direct stimulatory effect on mature cells.
In this review 5 studies dealing with healing of bones have been summarized. Different models were chosen: Geesink et al made a human fibular model, which proved to be a critical size defect, therefore very similar to the non human primate models which have been used in the preclinical studies (14) . They found that 6 out of 6 defects were not united in the control group while 5 out of 6 were united in OP-1 group. Thus, this was considered a proof of concept that BMPs had an effect in the human skeleton.
Friedlaender et al (9) chose a somewhat more complicated model with nonunions of the tibial shaft, comparing OP-1 treatment with the golden standard, autograft transplantation. They found that the results were in the same range with OP-1 as with the autograft. However, comparing the numbers, autograft lead to a higher degree of success for all criteria except for infection at the nonunion site. Nonunion is probably the indication where BMPs have reached extensive use outside of studies for long bones. In our own experience this has so far been successful in 5 out of 5 complex cases where we have used rhBMP-2.
Maniscalco and co-workers (8) studied tibial fractures treated by OP-1 and external fixators. They found no effect of OP-1 in closed tibial shaft fractures, but the study was clearly underpowered with only 7patients in each group. In contrast, Govender's -pivotal study included 450 patients on all continents, probably one of the largest multicenter studies ever undertaken in orthopaedic trauma. A high dose of BMP-2 reduced the rate of reoperation to promote healing by 44% compared to the control group. Also, wound healing was stimulated in this study, pointing to a pleiotropic effect for the BMPs (15) .
Finally Delloye reported on allograft non unions of fractures and found no positive effects of either BMP-2 or BMP-7.
These human studies show that there is an effect of BMPs in stimulating healing of bone, at least when the model is appropriate and the power of the study is adequate. Models chosen will influence results and allograft unions seem to be a fairly complicated matter. A prerequisite for BMPs to have a positive effect is the presence of a source for mesenchymal stem cells, which can migrate in and differentiate. In the Govender study instructions were that the collagen sponge with BMP should be covered with muscle, since muscle is probably the most important source for stem cells in long bone healing together with the marrow and periosteum (16) . The other studies have not reported details on how the BMP collagen complex was covered, or in Maniscalcos study how the OP-1 was injected intramedullary in a one week old fracture. In the tumour cases of Delloye a lot of the muscles around the bone may have been resected in the initial tumour resection and the sources for mesenchymal stems cells might have been scarce. Therefore, it may seem as though the BMPs should be in contact with muscle to exert its maximal effect through chemotaxis and differentiation of mesenchymal stem cells.
The limitations of the BMPs should be kept in mind now that these rather expensive devices have become available for clinical use. Its use have already become frequent in spinal fusion (17) , while in the trauma market it has, so far, been used to a lesser extent. The reason for this may also be an assumption that it is a complicated implant procedure. We have, however, used the rhBMP-2 on a collagen sponge and experienced this to be a rather simple procedure. Instructions for use of OP-1 also indicate its simplicity. A difference between the two is that the BMP-2 is kept on one collagen sponge while the OP-1/collagen is more like slurry and maybe therefore more complicated to retain at the fracture site. Use of the BMPs in trauma will probably increase when injectable formulations appear on the market; there are reports of calcium phosphate pastes mixed with rhBMP-2 that can be injected (18) . With this, most fractures can be treated by injections, also probably possible for delayed unions or non unions. This may open a totally new treatment modality, which will hopefully benefit our patients.
CONCLUSION
Pre-clinical evidence for the effects of BMPs in promoting bone healing is clear in every species from mice to non human primates. Five papers reviewed here show that BMPs also have an effect in human long bone healing. The development of new carriers, making injection of the BMPs possible, will further increase our possibilities to stimulate bone healing.
